Abstract
TRACERx is a multicentre, prospective study recruiting patients with early stage non small cell lung cancer. By leveraging longitudinal CT imaging, patterns and timing of metastatic spread and tumour growth rates can be tracked lesion by lesion. Circulating tumour DNA (ctDNA) in longitudinal plasma samples can be mapped to imaging timepoints to assess their role as a biomarker in monitoring cancer progression and the impact of therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
